TY - JOUR
T1 - Geographic heterogeneity in the prevalence of human papillomavirus in head and neck cancer
AU - Anantharaman, Devasena
AU - Abedi-Ardekani, Behnoush
AU - Beachler, Daniel C.
AU - Gheit, Tarik
AU - Olshan, Andrew F.
AU - Wisniewski, Kathy
AU - Wunsch-Filho, Victor
AU - Toporcov, Tatiana N.
AU - Tajara, Eloiza H.
AU - Levi, José Eduardo
AU - Moyses, Raquel A.
AU - Boccia, Stefania
AU - Cadoni, Gabriella
AU - Rindi, Guido
AU - Ahrens, Wolfgang
AU - Merletti, Franco
AU - Conway, David I.
AU - Wright, Sylvia
AU - Carreira, Christine
AU - Renard, Helene
AU - Chopard, Priscilia
AU - McKay-Chopin, Sandrine
AU - Scelo, Ghislaine
AU - Tommasino, Massimo
AU - Brennan, Paul
AU - D'Souza, Gypsyamber
N1 - Funding Information:
The authors acknowledge the contribution of GENCAPO (Brazilian Head and Neck Genome Project) for clinical samples and for clinical and pathological data collection (complete list of members and affiliations presented at http://www.gencapo.famerp.br).
Publisher Copyright:
© 2017 IARC/WHO
PY - 2017/5/1
Y1 - 2017/5/1
N2 - Human papillomavirus (HPV) causes oropharyngeal squamous cell carcinoma (OPSCC), although strongly divergent results have been reported regarding the prevalence of HPV16 in different countries, whether this represents important differences in etiology remains unclear. Applying rigorous protocols for sample processing, we centrally evaluated 1,420 head and neck tumors (533 oropharynx, 395 oral cavity and 482 larynx) from studies conducted in the US, Europe and Brazil for mucosal HPV DNA and p16INK4a expression to evaluate regional heterogeneity in the proportion of HPV16-associated OPSCC and other head and neck cancer, and to assess covariates associated with the risk of HPV16-positive OPSCC. While majority of OPSCC in the US (60%) were HPV16-positive, this proportion was 31% in Europe and only 4% in Brazil (p < 0.01). Similar differences were observed for other head and neck tumors, ranging from 7% in the US and 5% in Europe, to 0% in South America. The odds of HPV16-positive OPSCC declined with increasing pack years of smoking (OR: 0.75; 95% CI: 0.64–0.87) and drink years of alcohol use (OR: 0.64; 95% CI: 0.54–0.76). These results suggest that while the contribution of HPV16 is substantial for the oropharynx, it remains limited for oral cavity and laryngeal cancers.
AB - Human papillomavirus (HPV) causes oropharyngeal squamous cell carcinoma (OPSCC), although strongly divergent results have been reported regarding the prevalence of HPV16 in different countries, whether this represents important differences in etiology remains unclear. Applying rigorous protocols for sample processing, we centrally evaluated 1,420 head and neck tumors (533 oropharynx, 395 oral cavity and 482 larynx) from studies conducted in the US, Europe and Brazil for mucosal HPV DNA and p16INK4a expression to evaluate regional heterogeneity in the proportion of HPV16-associated OPSCC and other head and neck cancer, and to assess covariates associated with the risk of HPV16-positive OPSCC. While majority of OPSCC in the US (60%) were HPV16-positive, this proportion was 31% in Europe and only 4% in Brazil (p < 0.01). Similar differences were observed for other head and neck tumors, ranging from 7% in the US and 5% in Europe, to 0% in South America. The odds of HPV16-positive OPSCC declined with increasing pack years of smoking (OR: 0.75; 95% CI: 0.64–0.87) and drink years of alcohol use (OR: 0.64; 95% CI: 0.54–0.76). These results suggest that while the contribution of HPV16 is substantial for the oropharynx, it remains limited for oral cavity and laryngeal cancers.
KW - HPV16
KW - alcohol
KW - head and neck cancer
KW - oropharynx
KW - prevalence
KW - smoking
UR - http://www.scopus.com/inward/record.url?scp=85012281761&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85012281761&partnerID=8YFLogxK
U2 - 10.1002/ijc.30608
DO - 10.1002/ijc.30608
M3 - Article
C2 - 28108990
AN - SCOPUS:85012281761
VL - 140
SP - 1968
EP - 1975
JO - International Journal of Cancer
JF - International Journal of Cancer
SN - 0020-7136
IS - 9
ER -